- Exchange: NASDAQ CM
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Apricus Biosciences Inc
+ Add to WatchlistAPRI:US
2.5800 USD 0.0700 2.64%As of 20:10:00 ET on 05/24/2013.
Snapshot for Apricus Biosciences Inc (APRI)
| Open: | 2.6800 | Day's Range: | 2.5600 - 2.7000 | Volume: | 1,551,980 |
|---|---|---|---|---|---|
| Previous Close: | 2.5800 | 52wk Range: | 1.8900 - 3.6299 | 1-Yr Rtn: | -4.44% |
Key Statistics for APRI
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | - |
| Est. EPS (USD) (12/2013) | -0.5300 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 94.28 |
| Shares Outstanding (M) | 36.54 |
| 30 Day Average Volume | 514,753 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/09/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for APRI
Company Profile & Key Executives for APRI
Apricus Biosciences Inc. is a bio-technology company. The Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer.
| Richard W PascoeChief Executive Officer | Randy BerholtzExec VP/Secretary/General Counsel |
| Steve MartinSenior VP/CFO | Edward CoxVP:Corporate Dev & Investor Relations |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
APRI News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page